GoodRx Holdings earnings release, August 5, 2026

GoodRx Holdings, Inc. (GDRX) · Form 8-K, Item 2.02 · Filed · SEC filing

GOODRX REPORTS

SECOND

QUARTER

2026

RESULTS

Pharma Direct and Subscription Revenue Increased

76% and

39%, Respectively, Year-Over-Year

Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations

SANTA MONICA, Calif. -- (

August 5, 2026) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the

“Company”), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of

2026.

Second

Quarter

2026

Highlights

• Revenue of

$200.4 million

• Net income of

$8.5 million;

Net income margin of

4.3%

• Adjusted Net Income¹ of

$26.8 million; Adjusted Net Income Margin¹ of

13.4%

• Adjusted EBITDA¹ of

$63.7 million; Adjusted EBITDA Margin¹ of

31.8%

• Net cash provided by operating activities of

$80.8 million

“We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that those investments are translating into stronger performance,” said Wendy Barnes, President and Chief Executive Officer of

GoodRx. “We believe this progress is accelerating our return to growth and strengthening the long-term durability of

GoodRx.”

1.

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Adjusted EBITDA Margin and Adjusted Net Income Margin are defined as Adjusted EBITDA and Adjusted Net

Income, respectively, divided by Adjusted Revenue. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and reconciliations to the most directly comparable GAAP measures.

Second

Quarter

2026

Financial Overview

(all comparisons are made to the same period of the prior year unless otherwise noted):

Revenue decreased

1% to

$200.4 million compared to

$203.1 million.

Prescription transactions revenue decreased

26% to

$106.4 million compared to

$143.1 million, primarily driven by a decrease in the number of our Monthly Active Consumers due to the broader changes in the retail pharmacy landscape including store closures and volume reduction in one of our integrated savings programs, as well as the deliberate shift of product and marketing investment toward our new subscription offerings. The year-over-year decrease was also due to lower unit economics which we expect to continue in the near-term as we made deliberate decisions to favor long-term durability and certainty.

Subscription revenue increased

39% to

$28.5 million compared to

$20.5 million, primarily driven by the expansion and growth of our condition-specific subscription programs, in particular weight loss, as well as a resulting increase in the number of subscription plans.

Pharma Direct revenue increased

76% to

$61.6 million compared to

$35.0 million, driven by organic growth as we continued to expand our market penetration with pharma manufacturers and other customers, in particular our GLP-1 access programs, which are part of our consumer direct pricing.

Net income was

$8.5 million compared to

$12.8 million.

Net income margin was

4.3% compared to

6.3%. Adjusted Net

Income¹ was

$26.8 million compared to

$33.9 million.

Adjusted EBITDA¹ was

$63.7 million compared to

$69.4 million. Adjusted EBITDA Margin¹ was

31.8% compared to

34.2%.

Cash Flow and Capital Allocation

Net cash provided by operating activities in the second quarter was

$80.8 million compared to

$49.6 million in the comparable period last year. As of

June 30, 2026, we had cash and cash equivalents of

$296.1 million and total outstanding debt of

$492.5 million.

We are focused on a disciplined approach to capital allocation, centered on furthering our mission and creating stockholder value. Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M&A that aligns with our strategic priorities. These capital allocation priorities support our long-term growth strategy while also providing flexibility to navigate near-term challenges.

Exhibit 99.1

Guidance

Management is raising its full-year 2026 guidance as follows

:

“We exceeded our expectations in the second quarter, with Pharma Direct revenue increasing 76% year-over-year and subscription revenue increasing 39% year-over-year,” said Justin Fengler, incoming Chief Financial Officer and current Chief

Strategy & Operations Officer of GoodRx. “Based on our strong first-half performance, we are raising our full-year revenue and Adjusted EBITDA guidance.”

2.

Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental informational purposes only. We have not reconciled our Adjusted

EBITDA guidance to GAAP net income or loss because we do not provide guidance for such GAAP measure due to the uncertainty and potential variability of stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted

EBITDA and the most directly comparable GAAP measure. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on our future GAAP net income or loss.

Investor Conference Call and Webcast

GoodRx management will host a conference call and webcast tomorrow, August 6, 2026, at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.

To access the conference call, please pre-register using the following link

: https://register-conf.media-server.com/register/BI2d7e976f9edd481db1351e5bb1902f6a... (truncated)oin.

The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the

Company’s investor relations website at https://investors.goodrx.com for at least 30 days.

Exhibit 99.1

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly

25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, pharmacy benefit managers, pharmaceutical manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped

Americans save over

$100 billion on the cost of their medications.

GoodRx periodically posts information that may be important to investors on its investor relations website at https:// investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Investor Contact

GoodRx

Aubrey Reynolds ir@goodrx.com

Press Contact

GoodRx

Lauren Casparis lcasparis@goodrx.com

Exhibit 99.1

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue200,411203,070394,417406,040
Costs and operating expenses:Cost of revenue, exclusive of depreciation and amortization presented separately below20,99913,35041,15526,714
Costs and operating expenses:Product development and technology26,71129,93356,88861,075
Costs and operating expenses:Sales and marketing81,98684,870163,039169,412
Costs and operating expenses:General and administrative24,81428,37951,63358,009
Costs and operating expenses:Depreciation and amortization22,26919,72944,06140,641
Costs and operating expenses:Total costs and operating expenses176,779176,261356,776355,851
Costs and operating expenses:Operating income23,63226,80937,64150,189
Other expense, net:Other income625694625694
Other expense, net:Interest income1,0192,8032,4166,735
Other expense, net:Interest expense-9,810-10,729-19,577-21,373
Other expense, net:Total other expense, net-8,166-7,232-16,536-13,944
Other expense, net:Income before income taxes15,46619,57721,10536,245
Other expense, net:Income tax expense-6,930-6,734-11,400-12,350
Other expense, net:Net income8,53612,8439,70523,895
Earnings per share:Basic0.030.040.030.06
Earnings per share:Diluted0.020.040.030.06
Weighted average shares used in computing earnings per share:Basic339,277356,623339,839367,847
Weighted average shares used in computing earnings per share:Diluted348,058357,159344,676368,345
Stock-based compensation included in costs and operating expenses:Cost of revenue58122110222
Stock-based compensation included in costs and operating expenses:Product development and technology4,5546,3238,76211,993
Stock-based compensation included in costs and operating expenses:Sales and marketing4,2035,9298,45211,811
Stock-based compensation included in costs and operating expenses:General and administrative7,7789,04115,77816,563

Income Statement

, revenue comprised of the following: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Prescription transactions revenue106,390143,064220,082291,987
Subscription revenue28,51420,46352,90741,480
Pharma Direct revenue61,62834,981113,85863,629
Other revenue3,8794,5627,5708,944
Total revenue200,411203,070394,417406,040

Income Statement

measure calculated in accordance with GAAP, with Adjusted EBITDA Margin: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income8,53612,8439,70523,895
Adjusted to exclude the following:Interest income-1,019-2,803-2,416-6,735
Adjusted to exclude the following:Interest expense9,81010,72919,57721,373
Adjusted to exclude the following:Income tax expense6,9306,73411,40012,350
Adjusted to exclude the following:Depreciation and amortization22,26919,72944,06140,641
Adjusted to exclude the following:Other income-625-694-625-694
Adjusted to exclude the following:Acquisition related expenses27552726
Adjusted to exclude the following:Restructuring related expenses5725465,8581,765
Adjusted to exclude the following:Legal settlement expenses355355
Adjusted to exclude the following:Stock-based compensation expense16,59321,41533,10240,589
Adjusted to exclude the following:Payroll tax expense related to stock-based compensation3995498211,234
Adjusted to exclude the following:Loss on operating lease asset4,409
Adjusted to exclude the following:Adjusted EBITDA63,74069,403122,010139,208
Adjusted to exclude the following:Revenue200,411203,070394,417406,040
Adjusted to exclude the following:Net income margin4.3%6.3%2.5%5.9%
Adjusted to exclude the following:Adjusted EBITDA Margin31.8%34.2%30.9%34.3%

Income Statement

Three Months Ended June 30, — Income Margin, and Adjusted Earnings Per Share, respectively: (dollars in thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income8,53612,8439,70523,895
Adjusted to exclude the following:Amortization of intangibles related to acquisitions and restructuring related activities2,9132,7935,8285,586
Adjusted to exclude the following:Other income-625-694-625-694
Adjusted to exclude the following:Acquisition related expenses27552726
Adjusted to exclude the following:Restructuring related expenses5725465,8581,765
Adjusted to exclude the following:Legal settlement expenses355355
Adjusted to exclude the following:Stock-based compensation expense16,59321,41533,10240,589
Adjusted to exclude the following:Payroll tax expense related to stock-based compensation3995498211,234
Adjusted to exclude the following:Loss on operating lease asset4,409
Adjusted to exclude the following:Income tax effects of excluded items and adjustments for valuation allowance and excess tax benefits/deficiencies from equity awards-1,879-3,904-5,383-8,899

Income Statement

with GAAP: (in thousands)

GAAP – Three Months Ended June 30, – 2026GAAP – Three Months Ended June 30, – 2025Adjusted – Three Months Ended June 30, – 2026Adjusted – Three Months Ended June 30, – 2025GAAP – Six Months Ended June 30, – 2026GAAP – Six Months Ended June 30, – 2025Adjusted – Six Months Ended June 30, – 2026Adjusted – Six Months Ended June 30, – 2025
Cost of revenue20,99913,35020,92213,23441,15526,71441,00626,492
% of Revenue10.0%7.0%10.0%7.0%10.0%7.0%10.0%7.0%
Product development and technology26,71129,93321,86323,50056,88861,07544,69247,490
% of Revenue13.0%15.0%11.0%12.0%14.0%15.0%11.0%12.0%
Sales and marketing81,98684,87077,51577,966163,039169,412152,599156,370
% of Revenue41.0%42.0%39.0%38.0%41.0%42.0%39.0%39.0%
General and administrative24,81428,37916,37118,96751,63358,00934,11036,480
% of Revenue12.0%14.0%8.0%9.0%13.0%14.0%9.0%9.0%
Depreciation and amortization22,26919,72919,35616,93644,06140,64138,23335,055
% of Revenue11.0%10.0%10.0%8.0%11.0%10.0%10.0%9.0%
Operating income23,63226,80944,38452,46737,64150,18983,777104,153
% of Revenue12.0%13.0%22.0%26.0%10.0%12.0%21.0%26.0%

Income Statement

measure to its most directly comparable financial measure calculated in accordance with GAAP: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cost of revenue20,99913,35041,15526,714
Acquisition related expenses-17-36
Restructuring related expenses1210
Stock-based compensation expense-58-122-110-222
Payroll tax expense related to stock-based compensation-2-6-3-10
Adjusted cost of revenue20,92213,23441,00626,492
Product development and technology26,71129,93356,88861,075
Acquisition related expenses-89-175
Restructuring related expenses202-2,872-907
Stock-based compensation expense-4,554-6,323-8,762-11,993
Payroll tax expense related to stock-based compensation-205-312-387-685
Adjusted product development and technology21,86323,50044,69247,490
Sales and marketing81,98684,870163,039169,412
Acquisition related expenses-169-316
Restructuring related expenses-848-1,479-935
Stock-based compensation expense-4,203-5,929-8,452-11,811
Payroll tax expense related to stock-based compensation-99-127-193-296
Adjusted sales and marketing77,51577,966152,599156,370
General and administrative24,81428,37951,63358,009
Acquisition related expenses-26
Restructuring related expenses-57288-1,50767
Legal settlement expenses-355-355
Stock-based compensation expense-7,778-9,041-15,778-16,563
Payroll tax expense related to stock-based compensation-93-104-238-243
Loss on operating lease asset-4,409
Adjusted general and administrative16,37118,96734,11036,480
Depreciation and amortization22,26919,72944,06140,641
Amortization of intangibles related to acquisition-2,913-2,793-5,828-5,586
Adjusted depreciation and amortization19,35616,93638,23335,055
Operating income23,63226,80937,64150,189
Amortization of intangibles related to acquisition2,9132,7935,8285,586
Acquisition related expenses27552726
Restructuring related expenses5725465,8581,765
Legal settlement expenses355355
Stock-based compensation expense16,59321,41533,10240,589
Payroll tax expense related to stock-based compensation3995498211,234
Loss on operating lease asset4,409
Adjusted operating income44,38452,46783,777104,153

Balance Sheet

(Unaudited) (in thousands, except par values)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents296,113261,820
Current assetsAccounts receivable, net182,140235,746
Current assetsPrescription reimbursement assets1,076,01298,331
Current assetsPrepaid expenses and other current assets45,06247,205
Current assetsTotal current assets1,599,327643,102
Current assetsProperty and equipment, net11,51412,268
Current assetsGoodwill430,331430,331
Current assetsIntangible assets, net58,25464,082
Current assetsCapitalized software, net140,300139,261
Current assetsOperating lease right-of-use assets, net27,63028,808
Current assetsDeferred tax assets, net47,33557,111

Cash Flow

(Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activitiesNet income9,70523,895
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization44,06140,641
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of debt issuance costs and discounts932869
Adjustments to reconcile net income to net cash provided by operating activities:Non-cash operating lease expense1,9102,065
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation expense33,10240,589
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes9,776
Adjustments to reconcile net income to net cash provided by operating activities:Loss on operating lease asset4,409
Adjustments to reconcile net income to net cash provided by operating activities:Other1,069456
Changes in operating assets and liabilities:Accounts receivable53,606-43,093
Changes in operating assets and liabilities:Prescription reimbursement assets (1)-977,681-16,027
Changes in operating assets and liabilities:Prepaid expenses and other assets (1)2,929231
Changes in operating assets and liabilities:Accounts payable (1)-9,8713,579
Changes in operating assets and liabilities:Prescription reimbursement liabilities (1)909,856-1,313
Changes in operating assets and liabilities:Accrued expenses and other current liabilities (1)16,0635,585
Changes in operating assets and liabilities:Operating lease liabilities-2,912-3,187
Changes in operating assets and liabilities:Other liabilities125294
Changes in operating assets and liabilities:Net cash provided by operating activities92,67058,993
Cash flows from investing activitiesPurchase of property and equipment-1,498-532
Cash flows from investing activitiesAcquisition-30,000
Cash flows from investing activitiesCapitalized software-34,555-39,659
Cash flows from investing activitiesNet cash used in investing activities-36,053-70,191
Cash flows from financing activitiesPayments on long-term debt-2,500-2,500
Cash flows from financing activitiesRepurchases of Class A common stock-14,520-145,888
Cash flows from financing activitiesProceeds from exercise of stock options953
Cash flows from financing activitiesEmployee taxes paid related to net share settlement of equity awards-5,768-8,305
Cash flows from financing activitiesProceeds from employee stock purchase plan369860
Cash flows from financing activitiesNet cash used in financing activities-22,324-155,830
Cash flows from financing activitiesNet change in cash and cash equivalents34,293-167,028
Cash and cash equivalentsBeginning of period261,820448,346
Cash and cash equivalentsEnd of period296,113281,318
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future results of operations and financial position, industry and business trends, including uncertainty in the macro environment, the impact of trends impacting retail pharmacies on our future financial results, the potential impact of the new government-sponsored direct-to-consumer platform called

“

TrumpRx.gov”

(“TrumpRx”) and other evolving federal initiatives on our business, our value proposition, our business strategy and our ability to execute on our strategic priorities including expanding manufacturer partnerships, growing differentiated subscription offerings and strengthening retail relationships, our plans, market opportunity, ability to preserve margin strength and long-term growth prospects, our capital allocation priorities, Pharma Direct as the future key growth driver of our business, and the future of prescription access. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of growth; our recent growth rates may not be sustainable or indicative of future growth; our ability to achieve broad market education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and the significant impact of pricing structures negotiated by industry participants; our general inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers; the competitive nature of our industry; risks related to pandemics, epidemics, or outbreak of infectious disease; the accuracy of our estimate of our addressable market and other operational metrics; our ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive perception of our platform or maintain and enhance our brand; risks related to any failure to maintain effective internal control over financial reporting; risks related to use of social media, emails, text messages, and other messaging channels as part of our marketing strategy; our dependence on our information technology systems and those of our third-party vendors, and risks related to any failure or significant disruptions thereof; risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology, and cybersecurity; risks related to the use of AI and machine learning in our business; risks related to a decrease in consumer willingness to receive correspondence or any technical, legal, or any other restrictions to send such correspondence; risks related to any failure to comply with applicable data protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other requirements; our ability to utilize our net operating loss carryforwards and certain other tax attributes; the risk that we may be unable to realize expected benefits from our restructuring and cost reduction efforts; our ability to... (tr develop, motivate and retain well-qualified employees; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or delays in service on our apps or websites or any undetected errors or design faults; our reliance on third-party platforms to distribute our platform and offerings, including software as-a-service technologies; systems failures or other disruptions in the operations of these parties on which we depend; risks related to climate change; risks associated with environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating in the healthcare industry; risks related to our organizational structure; litigation related risks; our ability to accurately forecast revenue and appropriately plan our expenses in the future; risks related to general economic factors, natural disasters, or other unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate which could materially and adversely affect our results of operations; risks related to the healthcare reform legislation and other proposed or future changes impacting the healthcare industry and healthcare spending, including the new platform

TrumpRx, which may adversely affect our business, financial condition and results of operations; as well as the other important factors discussed in the section entitled “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Exhibit 99.1

Key Operating Metrics

Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code to purchase a prescription medication in a given calendar month and have saved money compared to the list price of the medication. A unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active

Consumers do not include subscribers to our subscription offerings, consumers of our Pharma Direct offering, or consumers who used our telehealth offering. When presented for a period longer than a month, Monthly Active Consumers are averaged over the number of calendar months in such period. Monthly Active Consumers from acquired companies are included beginning from the acquisition date. As our business continues to evolve, we are reassessing the Monthly Active

Consumers metric as a primary indicator of performance to ensure it aligns with how we measure growth and profitability.

Subscription plans represent the ending subscription plan balance across our subscription offerings, GoodRx Gold, condition-specific related subscription programs (first launched in June 2025), RxSmartSaver+ powered by GoodRx

(launched in July 2025) and GoodRx Companion

(monthly and annual plans launched in May and July 2026, respectively).

For GoodRx Gold and RxSmartSaver+, each subscription plan may represent more than one subscriber since family subscription plans may include multiple members.

Exhibit 99.1

GoodRx Holdings, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

Exhibit 99.1

GoodRx Holdings, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

Exhibit 99.1

GoodRx Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

_____________________________________________________

(1)

Prior to December 31, 2025, prescription reimbursement assets were presented as a component of prepaid expenses and other current assets, and prescription reimbursement liabilities as a component of accounts payable and accrued expenses and other current liabilities. Prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on previously reported cash flows provided by operating activities.

Exhibit 99.1

For the three and six months ended June 30, 2026 and

2025, revenue comprised of the following:

Exhibit 99.1

Non-GAAP Financial Measures

Adjusted Revenue and metrics presented as a percentage of Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA

Margin, Adjusted Net Income, Adjusted Net Income Margin, and Adjusted Earnings Per Share are supplemental measures of our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and operating expense on our condensed consolidated statements of operations on an adjusted basis to arrive at adjusted operating income. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures."

We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated with restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past or future underlying performance of the business. For the current period and full year of

2025, revenue was equal to Adjusted..enue. In addition, we expect revenue for the full year of

2026 to equal Adjusted Revenue.

We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and amortization, and as further adjusted for, as applicable for the periods presented, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of business, and other income or expense, net. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of

Adjusted Revenue.

We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods presented, amortization of intangibles related to acquisitions and restructuring activities, acquisition related expenses, stock- based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of business, other income or expense, net, and as further adjusted for estimated income tax on such adjusted items.

Our adjusted taxes also exclude

(i) the valuation allowance recorded against certain of our net deferred tax assets that was recognized in accordance with GAAP and any subsequent releases of the valuation allowance, and (ii) all tax benefits/ expenses resulting from excess tax benefits/deficiencies in connection with stock-based compensation. Adjusted Net

Income Margin represents Adjusted Net Income as a percentage of Adjusted Revenue.

Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share – basic is equal to our

GAAP weighted average shares – basic and the weighted average shares we use in computing Adjusted Earnings Per

Share – diluted is equal to either GAAP weighted average shares – basic or GAAP weighted average shares – diluted, depending on whether we have adjusted net loss or adjusted net income, respectively.

We also assess our performance by evaluating each cost and operating expense on our condensed consolidated statements of operations on a non-GAAP, or adjusted, basis to arrive at adjusted operating income. The adjustments to these cost and operating expense items include, as applicable for the periods presented, acquisition related expenses, amortization of intangibles related to acquisitions and restructuring activities, stock-based compensation expense, payroll tax expense related to stock-based compensation, financing related expenses, restructuring related expenses, legal settlement expenses, loss on operating lease assets, and gain on sale of business. Adjusted operating income is Adjusted

Revenue less non-GAAP costs and operating expenses.

We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted

Revenue, Adjusted EBITDA, and Adjusted EBITDA Margin are also key measures we use to assess our financial performance and are also used for internal planning and forecasting purposes. In addition, Adjusted Revenue, Adjusted

EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Earnings Per Share are frequently used by analysts, investors and other interested parties to evaluate and assess performance.

The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain costs that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.

Exhibit 99.1

The following table presents a reconciliation of net income, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted EBITDA, and presents net income margin, the most directly comparable financial measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:

Exhibit 99.1

The following tables present a reconciliation of net income and calculations of net income margin and earnings per share, the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted Net Income, Adjusted Net

Income Margin, and Adjusted Earnings Per Share, respectively:

Exhibit 99.1

The following table presents (i) each non-GAAP, or adjusted, cost and expense and operating income measure together with its most directly comparable financial measure calculated in accordance with GAAP; and (ii) each adjusted cost and expense and adjusted operating income as a percentage of Adjusted Revenue together with each GAAP cost and expense and operating income as a percentage of revenue, the most directly comparable financial measure calculated in accordance with GAAP:

Exhibit 99.1

The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense and operating income measure to its most directly comparable financial measure calculated in accordance with GAAP:

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · GoodRx Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.